Neurocrine Biosciences Inc
SWB:NB3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Neurocrine Biosciences Inc
SWB:NB3
|
US |
|
Advantest Corp
OTC:ADTTF
|
JP |
|
C
|
Compass Minerals International Inc
XBER:CM8
|
US |
|
Ai-Media Technologies Ltd
ASX:AIM
|
AU |
|
Premia SA
F:3FDA
|
GR |
Wall St Price Targets
NB3 Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for NB3 is 168.36 EUR with a low forecast of 125.89 EUR and a high forecast of 223.58 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NB3's stock price target?
Price Target
168.36
EUR
According to Wall Street analysts, the average 1-year price target for NB3 is 168.36 EUR with a low forecast of 125.89 EUR and a high forecast of 223.58 EUR.
What is the Revenue forecast for Neurocrine Biosciences Inc?
Projected CAGR
13%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 13%.
What is the Gross Profit forecast for Neurocrine Biosciences Inc?
Projected CAGR
13%
The compound annual growth rate for Gross Profit over the next 8 years is 13%.
What is the Operating Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
26%
Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 26%.
What is the Pre-Tax Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
38%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 46%. The projected CAGR for the next 3 years is 38%.
What is the Net Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
30%
Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 30%.
